Eli Lilly 2026年6月4日 Pharmalittle: We're reading about fewer pharma investments in Germany, growing U.S. layoffs, and more - statnews.com
Eli Lilly 2026年6月4日 Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Eli Lilly 2026年6月4日 Eli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com
Eli Lilly 2026年6月3日 Lilly, Boehringer to slash at least $1B each from planned investments in Germany - Fierce Pharma
Eli Lilly 2026年6月3日 Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases - Fierce Biotech
Eli Lilly 2026年6月1日 Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear - Fierce Biotech
Eli Lilly 2026年5月28日 Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron's
Eli Lilly 2026年5月28日 CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo - Fierce Pharma
Eli Lilly 2026年5月26日 Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues - Fierce Biotech
Eli Lilly 2026年5月26日 Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company - investor.lilly.com
Eli Lilly 2026年5月25日 Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study - statnews.com
Eli Lilly 2026年5月25日 A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - PR Newswire